Sera Prognostics, Inc., (SERA): Price and Financial Metrics


Sera Prognostics, Inc., (SERA): $1.32

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SERA Stock Summary

  • SERA PROGNOSTICS INC's stock had its IPO on July 15, 2021, making it an older stock than merely 3.61% of US equities in our set.
  • With a price/sales ratio of 177.43, SERA PROGNOSTICS INC has a higher such ratio than 98.35% of stocks in our set.
  • With a year-over-year growth in debt of 732.41%, SERA PROGNOSTICS INC's debt growth rate surpasses 97.28% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to SERA PROGNOSTICS INC, a group of peers worth examining would be BASE, MASS, LVOX, VORB, and RNLX.
  • To dig deeper into the stock's financial statements, go to SERA's page on browse-edgar?action=getcompany&CIK=0001534969.

SERA Valuation Summary

  • SERA's price/sales ratio is 178.6; this is 3620.83% higher than that of the median Healthcare stock.
  • SERA's price/sales ratio has moved down 14345.4 over the prior 17 months.

Below are key valuation metrics over time for SERA.

Stock Date P/S P/B P/E EV/EBIT
SERA 2022-11-25 178.6 0.4 -0.9 -0.1
SERA 2022-11-23 178.6 0.4 -0.9 -0.1
SERA 2022-11-22 173.4 0.4 -0.8 0.0
SERA 2022-11-21 174.7 0.4 -0.9 -0.1
SERA 2022-11-18 183.0 0.4 -0.9 -0.1
SERA 2022-11-17 173.4 0.4 -0.8 0.0

SERA Price Target

For more insight on analysts targets of SERA, see our SERA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.00 Average Broker Recommendation 1.17 (Strong Buy)

SERA Stock Price Chart Interactive Chart >

Price chart for SERA

SERA Price/Volume Stats

Current price $1.32 52-week high $10.66
Prev. close $1.32 52-week low $1.15
Day low $1.23 Volume 19,700
Day high $1.32 Avg. volume 70,595
50-day MA $1.49 Dividend yield N/A
200-day MA $2.25 Market Cap 40.94M

Sera Prognostics, Inc., (SERA) Company Bio


Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.


SERA Latest News Stream


Event/Time News Detail
Loading, please wait...

SERA Latest Social Stream


Loading social stream, please wait...

View Full SERA Social Stream

Latest SERA News From Around the Web

Below are the latest news stories about SERA PROGNOSTICS INC that investors may wish to consider to help them evaluate SERA as an investment opportunity.

FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Fors Marsh, a company dedicated to solving complex challenges through market research, are collaborating to provide Sera's PreTRM® Test to employees at Fors Marsh as part of their maternity benefits, effective January 1, 2023.

Yahoo | November 29, 2022

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT (Analyses aCross Congruent studies ReDucing Adverse pregNancy ouTcomes). The newly published study reports:

Yahoo | November 15, 2022

Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 12.50% and 2.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter ended September 30, 2022.

Yahoo | November 9, 2022

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern

Yahoo | November 4, 2022

Read More 'SERA' Stories Here

SERA Price Returns

1-mo 1.54%
3-mo -34.00%
6-mo 1.54%
1-year -86.90%
3-year N/A
5-year N/A
YTD -80.79%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7194 seconds.